Dataset Information


Transcription profiling by array of human ulcerative colitis samples with varying responses to infliximab

ABSTRACT: Infliximab, an anti-TNFa monoclonal antibody, is an effective treatment for ulcerative colitis (UC) inducing over 60% of patients to respond to treatment. Consequently, about 40% of patients do not respond. This study analyzed mucosal gene expression from patients enrolled in ACT1 to provide a predictive response signature for infliximab treatment. Experiment Overall Design: Twenty-two patients underwent colonoscopy with biopsy before infliximab treatment. Response to infliximab was defined as endoscopic and histologic healing at week 8 (P2, 5, 9, 10, 14, 15, 16, 17, 24, 27, 36, and 45 as responders; P3, 12, 13, 19, 28, 29, 32, 33, 34, and 47 as non-responders). Messenger RNA was isolated from pre-infliximab biopsies, labeled and hybridized to Affymetrix HGU133Plus_2.0 Array. The predictive response signature was verified by an independent data set.


ORGANISM(S): Homo sapiens  

PROVIDER: E-GEOD-12251 | ExpressionAtlas | 2014-08-04

REPOSITORIES: ExpressionAtlas

altmetric image


BACKGROUND AND AIMS: Infliximab is an effective treatment for ulcerative colitis with over 60% of patients responding to treatment and up to 30% reaching remission. The mechanism of resistance to anti-tumour necrosis factor alpha (anti-TNFalpha) is unknown. This study used colonic mucosal gene expression to provide a predictive response signature for infliximab treatment in ulcerative colitis. METHODS: Two cohorts of patients who received their first treatment with infliximab for refractory ulce  ...[more]

Similar Datasets

2009-09-05 | E-GEOD-12251 | ArrayExpress
2009-08-25 | GSE12251 | GEO
2013-05-30 | E-GEOD-35640 | ArrayExpress
2010-01-06 | E-GEOD-14580 | ArrayExpress
2010-01-07 | GSE14580 | GEO
2017-05-10 | PXD006475 | Pride
| GSE66698 | GEO
| GSE66699 | GEO
2010-10-02 | E-GEOD-18948 | ArrayExpress
| GSE110390 | GEO